BioArctic begins patient dosing in EXIST phase 2a study in Parkinson’s disease: Stockholm Saturday, December 7, 2024, 18:00 Hrs [IST] BioArctic AB (publ), a Swedish research-bas ...
BIIB122, previously known as DNL151, is a small molecule designed to inhibit LRRK2, mutations in which are the most common cause of inherited Parkinson's.
Exidavnemab is a monoclonal antibody designed to target aggregated forms of the protein α-synuclein, believed to play a role in the disease progression in different neurological disorders including ...